HOUSTON — Chimeric antigen receptor T-cell therapy (CAR T) has emerged as a game changer for the treatment of multiple myeloma (MM), but questions remain as to how — and when — the immunotherapy will ...

The analysis also found the therapy has a manageable safety profile. A new meta-analysis of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma (MM) suggests the treatment ...

Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell ...

The U.S. FDA’s Oncology Drugs Advisory Committee, in two separate sessions, took up the matters of Carvykti (ciltacabtagene autoleucel) from Johnson & Johnson and the Bristol Myers Squibb Co. product ...

That past goes back nearly 76 years to 1947, when Enzo Ferrari built the first Prancing Horse to wear the enamel Cavallino emblem bearing his name. To look at a Ferrari from the first decade of the ...

Patients with relapsed/refractory multiple myeloma (r/r MM) treated with Carsgen Therapeutics Holdings Ltd.’s CAR T therapy, zevorcabtagene autoleucel (zevor-cel, CT-053), have shown durable responses ...